Tumour immunology, vaccination and escape strategies

European Journal of Immunogenetics

Volumn 30, Issue 3, 2003, Pages 177-183

  Garcia Lora, A ^a   Algarra, I ^b   Collado, A ^a   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLELE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BIOLOGICAL MONITORING; CANCER; CANCER CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DOWN REGULATION; EFFECTOR CELL; GENE LOCUS; GENE LOSS; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHENOTYPING; MELANOMA; MOLECULAR BIOLOGY; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HAPLOTYPES; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES; TUMOR ESCAPE; UP-REGULATION; VACCINATION;

EID: 0037636151     PISSN: 09607420     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2370.2003.00384.x     Document Type: Review

References (63)

1. Abril, E., Mendez, R.E., Garcia, A., Serrano, A., Cabrera, T., Garrido, F. & Ruiz-Cabello, F. (1996) Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Tissue Antigens, 47, 391.
2. Algarra, I., Cabrera, T. & Garrido, F. (2000) The HLA crossroad in tumour immunology. Human Immunology, 61, 65.
3. 2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 52, 520.
4. 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proceedings of the National Academy of Sciences of the USA, 91, 4751.
5. Boon, T., Cerottini, J.C., Van den Eynde, B., van der Bruggen, P. & Van Pel, A. (1994) Tumor antigens recognized by T lymphocytes. Annual Review of Immunology, 12, 337.
6. Brady, C.S., Bartholomew, J.S., Burt, D.J., Duggan-Keen, M.F., Glenville, S., Telford, N., Little, A.M., Davidson, J.A., Jimenez, P., Ruiz-Cabello, E et al. (2000) Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens, 55, 401.
7. Browning, M., Petronzelli, F., Bicknell, D., Kraus, P., Rowan, A., Tonks, S., Murray, N., Bodmer, J. & Bodmer, W. (1996) Mechanism of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens, 47, 364.
8. Burnet, F.M. (1970) The concept of immunological surveillance. Progress in Experimental Tumor Research, 13, 1.
9. Cabrera, T., Sierra, A., Fernandez, M.A., Herruzo, A., Fabra, A. & Garrido, F. (1996) High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Human Immunology, 50, 127.
10. Cabrera, T., Collado, A., Fernández, M.A., Ferrón, A., Sancho, J., Ruiz-Cabello, F. & Garrido, F. (1998) High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens, 52, 114.
11. Cabrera, T., Salinero, J., Fernández, M.A., Garrido, A., Esquivias, J. & Garrido, F. (2000) High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Human Immunology, 61, 499.
12. Chen, H.L., Gabrilovich, D., Virmani, A., Ratnani, I., Girgis, K.R., Nadaf-Rahrov, S., Fernandez-Vina, M. & Carbone, D.P. (1996) Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. International Journal of Cancer, 67, 756.
13. Cohen, G.B., Gandhi, R.T., Davis, D.M., Mandelboim, O., Chen, B.K., Strominger, J.L. & Baltimore, D. (1999) The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity, 10, 661.
14. Coulie, P.G., Hanagiri, T. & Takenoyama, M. (2001) From tumor antigens to immunotherapy. International Journal of Clinical Oncology, 6, 163.
15. Dovhey, S.E., Ghosh, N.S. & Wright, K.L. (2000) Loss of interferon-γ inducibility of TAP1 and LMP2 in a renal cell lcarcinoma cell line. Cancer Research, 60, 5789.
16. Dranoff, G. (2002) Tumor immunology: immune recognition and tumor protection. Current Opinion in Immunology, 14, 161.
17. Ehrlich, P. (1909) Ueber den jetzigen Stand der Karzinomforschung. [The state of the art of cancer research.] Ned Tijdschr Geneeskd, 5, 273.
18. Festenstein, H. & Garrido, F. (1986) MHC antigens and malignancy. Nature, 332, 502.
19. Finn, O.J. & Forni, G. (2002) Prophylactic cancer vaccines. Current Opinion in Immunology, 14, 172.
20. Garcia Lora, A., Algarra, I., Gaforio, F., Ruiz-Cabello, F. & Garrido, F. (2001) Immunoselection by T lymphocytes generates repetitive MHC class I deficient metastatic tumor variants. International Journal of Cancer, 91, 109.
21. Garrido, F. & Algarra, I. (2001) MHC antigens and tumor escape from immune surveillance. Advances in Cancer Research, 83, 117.
22. Garrido, F., Festenstein, H. & Schirrmacher, V. (1976) Further evidence for derepression of H-2 and Ia like specificities of foreign haplotypes in mouse tumour cell lines. Nature, 261, 705.
23. Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F. & Stern, P.L. (1993) Natural history of HLA expression during tumour development. Immunology Today, 14, 491.
24. Garrido, F., Cabrera, T., López-Nevot, M.A. & Ruiz-Cabello, F. (1995) HLA Class I antigens in human tumors. Advances in Cancer Research, 67, 155.
25. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J., López-Botet, M., Duggan-Keen, M. & Stern, P.L. (1997) Implications for immune surveillance of altered class I phenotypes in humans tumors. Immunology Today, 18, 89.
26. Gattoni-Celli, S., Kirsch, K., Timpane, R. & Isselbacher, K.J. (1992) Beta 2-microglobulin gene is mutated in a human colon cancer cell line (HCT) deficient in the expression of HLA class I antigens on the cell surface. Cancer Research, 52, 1201.
27. 2-microglobulin mutations, HLA class I antigen loss and tumor progression in melanoma. Journal of Clinical Investigation, 101, 2720.
28. Ikeda, H., Lethé, B., Lehmann, F., van Baren, N., Baurain, J.F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T. et al. (1997) Characterization of an antigen that is recognized on a melanoma exhibiting, partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6, 199.
29. Klein, G., Sjögren, H.O., Klein, E. & Hellström, K.E. (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Research, 20, 1561.
30. Koopman, L.A., Corver, W.E., van der Slik, A.R., Giphar, M.J. & Fleuren, G.J. (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. Journal of Experimental Medicine, 20, 961.
31. Ljunggren, H.G. & Kärre, K. (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunology Today, 11, 237.
32. López Nevot, M.A., García, E., Pareja, E., Bonal, F.J., Martín, J., Ruiz-Cabello, F. & Garrido, F. (1986) Differential expression of HLA class I and II antigens in primary and metastatic melanomas. Journal of Immunogenetics, 13, 219.
33. Maleno, I., Lopez-Nevot, M.A., Cabrera, T., Salinero, J. & Garrido, F. (2002) Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunology and Immunotherapy, 51, 7389.
34. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y. et al. (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. International Journal of Cancer, 63, 883.
35. Marchand, M., Von Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M.H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y. et al. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. International Journal of Cancer, 80, 219.
36. Marin, R., Ruiz-Cabello, F., Pedrinaci, S., Mendez, R., Geraghty, D.E. & Garrido, F. (2003) Analysis of HLA-E in human tumours. Immunogenetics, 54, 767.
37. Marincola, F.M., Jaffee, E.M., Hicklin, D.J. & Ferrone, S. (2000) Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Advances in Immunology, 74, 181.
38. Mendez, R., Serrano, A., Jaeger, E., Maleno, I., Ruiz-Cabello, F., Knuth, A. & Garrido, F. (2001) Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens, 257, 508.
39. Momburg, F., Hermann, B., Moldenhauer, G. & Moller, P.B. (1987) B-cell lymphomas of high-grade malignancy frequently lack HLA-DR-DP and -DQ antigens and associated invariant chain. International Journal of Cancer, 40, 598.
40. Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M.C. & Moretta, L. (1996) Receptors for HLA class-I molecules in human natural killer cells. Annual Review of Immunology, 14, 619.
41. Natali, P.G., Giacomini, P., Bigotti, A., Imai, K., Nicotra, M.R. & Ferrone, S. (1983) Double determinant immunoassay to measure a human high-molecular-weight melanoma-associated antigen. Cancer Research, 43, 660.
42. Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. & Schadendorf, D. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine, 4, 328.
43. Old, L. & Chen, Y.T. (1998) New paths in human cancer serology. Journal of Experimental Medicine, 187, 1163.
44. Parmiani, G., Taramelli, A., Anichini, A., Andreola, S., Cascinelli, N. & Fossati, G. (1986) Phenotypic heterogeneity of HLA products on human melanoma cells. Journal of Immunogenetics, 13, 235.
45. Pellegrino, M.A., Ferrone, S., Reisfeld, R.A., Irie, R.F. & Golub, S.H. (1977) Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. Cancer, 40, 36.
46. 2-microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens, 53, 569.
47. Pérez, M., Cabrera, T., López Nevot, M.A., Gomez, M., Perán, E., Ruiz-Cabello, F. & Garrido, F. (1986) Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma. Journal of Immunogenetics, 13, 247.
48. Pittet, M.J., Zippelius, A., Valmori, D., Speiser, D.E., Cerottini, J.C. & Romero, P. (2002) Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends in Immunology, 23, 325.
49. Real, L.M., Cabrera, T., Canton, J., Kirkin, A.F., Garcia, A., Abril, E., Zeuthen, J., Ruiz-Cabello, F. & Garrido, F. (1998) In vivo and in vitro generation of a new altered HLA phenotype in melanoma tumour cell variants expressing a single HLA class I allele. International Journal of Cancer, 75, 317.
50. Renkvist, N., Castelli, C., Robbins, P.F. & Parmiani, G. (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunology and Immunotherapy, 50, 3.
51. Restifo, N.P., Esquivel, F., Kawakami, Y., Yewdell, J.W., Mule, J.J., Rosenberg, S.A. & Bennink, J.R. (1993) Identification of human cancers deficient in antigen processing. J Exp Med, 177, 265.
52. Rosa, F., Berissi, H., Weissenbach, J., Maroteaux, L., Fellous, M. & Revel, M. (1983) The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO Journal, 2, 239.
53. Ruiter, D.J., Bergman, W., Welvaart, K., Scheffer, E., van Vloten, W.A., Russo, C. & Ferrone, S. (1984) Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Research, 44, 3930.
54. Sanda, M.G., Restifo, N.P., Walsh, J.C., Kawakami, Y., Nelson, W.G., Pardoll, D.M. & Simons, J.W. (1995) Molecular characterization of defective antigen processing in human prostate cancer. Journal of the National Cancer Institute, 87, 280.
55. Schrier, P., Versteeg, R., Peltemburg, L., Plomp, A.C., van't Veer, L.J. & Krúse-Wolters, K.M. (1991) Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Seminars in Cancer Biology, 2, 73.
56. Seliger, B., Hohne, A., Jung, D., Kallfelz, M., Knuth, A., Jaeger, E., Bernhard, H., Momburg, F., Tampe, R. & Huber, C. (1997) Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Experimental Hematology, 25, 608.
57. Srivastava, P.K. (2000) Immunotherapy of human cancer: lessons from mice. Nature Immunology, 5, 363.
58. Thomas, L. (1959) Discussion of cellular and humoral aspects of the hypersensitivity states. Cellular and humoral aspects of the hypersensitive states; a symposium held at the New York Academy of Medicine (ed. by H. S. Lawrence), p. 529. Hoeber-Harper, New York.
59. Topalian, S.L. (2001) Tumor immunology. Current Opinion in Immunology, 13, 131.
60. Torres, M.J., Ruiz-Cabello, F., Skoudy, A., Berrozpe, G., Jiménez, P., Serrano, A., Real, F.X. & Garrido, F. (1996) Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens, 47, 372.
61. Townsend, A.R., Rothbard, J., Gotch, F.M., Bahadur, G., Wraith, D. & McMichael, A.J. (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell, 28, 959.
62. Wagner, S., Rebmann, V., Willers, C., Grosse-Wilde, H. & Goos, M. (2000) Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet, 356, 220.
63. Wang, Z., Marincola, F.M., Rivoltini, L., Parmiani, G. & Ferrone, S. (1999) Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. Journal of Experimental Medicine, 190, 205.